David M. Mott - Sep 23, 2021 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
Director
Signature
/s/ John A. Herrmann III, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Sep 23, 2021
Transactions value $
-$6,312,616
Form type
4
Date filed
9/24/2021, 05:10 PM
Previous filing
Jul 2, 2021
Next filing
Oct 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Sale -$1.44M -5.73K -8.82% $251.32 59.2K Sep 23, 2021 Direct F1
transaction NVAX Common Stock Sale -$1.91M -7.56K -12.76% $252.56 51.7K Sep 23, 2021 Direct F2
transaction NVAX Common Stock Sale -$1.96M -7.74K -14.99% $253.46 43.9K Sep 23, 2021 Direct F3
transaction NVAX Common Stock Sale -$695K -2.73K -6.22% $254.46 41.2K Sep 23, 2021 Direct F4
transaction NVAX Common Stock Sale -$306K -1.2K -2.91% $255.38 40K Sep 23, 2021 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $250.92 to $251.87, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $251.98 to $252.91, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $253.00 to $253.97, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F4 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $254.06 to $255.05, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F5 The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $255.11 to $255.60, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.